Katerina Radilova

Ms. Katerina Radilova

Institute of Organic Chemistry and Biochemistry of the CAS
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VZVáclav Zima
Václav Zima
Katerina RadilovaKaterina Radilova
Katerina Radilova
MKMilan Kožíšek
Milan Kožíšek
CACarlos Berenguer Albiñana
Carlos Berenguer Albiñana
EKElena Karlukova
Elena Karlukova
AMAleš Machara
Aleš Machara
The biological effects of flavonoids on mammal cells are diverse, ranging from scavenging free radicals and anti-cancer activity to anti-influenza activity. Despite appreciable effort to understand the anti-influenza activity of flavonoids, there is no clear consensus about their precise mode-of-action at a cellular level. Here, we report the development and validation of a screening assay based on AlphaScreen technology and illustrate its application for determination of the inhibitory potency of a large set of polyols against PA N-terminal domain (PA-Nter) of influenza RNA-dependent RNA polymerase featuring endonuclease activity. The most potent inhibitors we identified were luteolin with an IC50 of 72 ± 2 nM and its 8-C-glucoside orientin with an IC50 of 43 ± 2 nM. Submicromolar inhibitors were also evaluated by an in vitro endonuclease activity assay using single-stranded DNA, and the results were in full agreement with data from the competitive AlphaScreen assay. Using X-ray crystallography, we analyzed structures of the PA-Nter in complex with luteolin at 2.0 Å resolution and quambalarine B at 2.5 Å resolution, which clearly revealed the binding pose of these polyols coordinated to two manganese ions in the endonuclease active site. Using two distinct assays along with the structural work, we have presumably identified and characterized the molecular mode-of-action of flavonoids in influenza-infected cells.

14 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JGJiří Gregor
Jiří Gregor
Katerina RadilovaKaterina Radilova
Katerina Radilova
Jiří BryndaJiří Brynda
Jiří Brynda
JFJindřich Fanfrlík
Jindřich Fanfrlík
JKJan Konvalinka
Jan Konvalinka
MKMilan Kožíšek
Milan Kožíšek
Influenza A virus (IAV) encodes a polymerase composed of three subunits: PA, with endonuclease activity, PB1 with polymerase activity and PB2 with host RNA five-prime cap binding site. Their cooperation and stepwise activation include a process called cap-snatching, which is a crucial step in the IAV life cycle. Reproduction of IAV can be blocked by disrupting the interaction between the PB2 domain and the five-prime cap. An inhibitor of this interaction called pimodivir (VX-787) recently entered the third phase of clinical trial; however, several mutations in PB2 that cause resistance to pimodivir were observed. First major mutation, F404Y, causing resistance was identified during preclinical testing, next the mutation M431I was identified in patients during the second phase of clinical trials. The mutation H357N was identified during testing of IAV strains at Centers for Disease Control and Prevention. We set out to provide a structural and thermodynamic analysis of the interactions between cap-binding domain of PB2 wild-type and PB2 variants bearing these mutations and pimodivir. Here we present four crystal structures of PB2-WT, PB2-F404Y, PB2-M431I and PB2-H357N in complex with pimodivir. We have thermodynamically analysed all PB2 variants and proposed the effect of these mutations on thermodynamic parameters of these interactions and pimodivir resistance development. These data will contribute to understanding the effect of these missense mutations to the resistance development and help to design next generation inhibitors.

Verified
Journal Article
Open access
PDF file
Robert ReibergerRobert Reiberger
Robert Reiberger
Katerina RadilovaKaterina Radilova
Katerina Radilova
MKMichal Kráľ
Michal Kráľ
VZVáclav Zima
Václav Zima
PMPavel Majer
Pavel Majer
AMAleš Machara
Aleš Machara
The part of the influenza polymerase PA subunit featuring endonuclease activity is a target for anti-influenza therapies, including the FDA-approved drug Xofluza. A general feature of endonuclease inhibitors is their ability to chelate Mg2+ or Mn2+ ions located in the enzyme’s catalytic site. Previously, we screened a panel of flavonoids for PA inhibition and found luteolin and its C-glucoside orientin to be potent inhibitors. Through structural analysis, we identified the presence of a 3′,4′-dihydroxyphenyl moiety as a crucial feature for sub-micromolar inhibitory activity. Here, we report results from a subsequent investigation exploring structural changes at the C-7 and C-8 positions of luteolin. Experimental IC50 values were determined by AlphaScreen technology. The most potent inhibitors were C-8 derivatives with inhibitory potencies comparable to that of luteolin. Bio-isosteric replacement of the C-7 hydroxyl moiety of luteolin led to a series of compounds with one-order-of-magnitude-lower inhibitory potencies. Using X-ray crystallography, we solved structures of the wild-type PA-N-terminal domain and its I38T mutant in complex with orientin at 1.9 Å and 2.2 Å resolution, respectively.

1 January 2021 in Antiviral Research
Verified
Journal Article
Open access
JHJakub Hejdánek
Jakub Hejdánek
Katerina RadilovaKaterina Radilova
Katerina Radilova
PPPetr Pachl
Petr Pachl
JHJan Hodek
Jan Hodek
AMAleš Machara
Aleš Machara
MKMilan Kožíšek
Milan Kožíšek
Influenza viruses can cause severe respiratory infections in humans, leading to nearly half a million deaths worldwide each year. Improved antiviral drugs are needed to address the threat of development of novel pandemic strains. Current therapeutic interventions target three key proteins in the viral life cycle: neuraminidase, the M2 channel and RNA-dependent-RNA polymerase. Protein-protein interactions between influenza polymerase subunits are potential new targets for drug development. Using a newly developed assay based on AlphaScreen technology, we screened a peptide panel for protein-protein interaction inhibitors to identify a minimal PB1 subunit-derived peptide that retains high inhibition potential and can be further modified. Here, we present an X-ray structure of the resulting decapeptide bound to the C-terminal domain of PA polymerase subunit from pandemic isolate A/California/07/2009 H1N1 at 1.6 angstrom resolution and discuss its implications for the design of specific, potent influenza polymerase inhibitors.

21 July 2025 in bioRxiv
Verified
Preprint
Open access
JFJonas S. Fischer
Jonas S. Fischer
MWMatthias Wojtynek
Matthias Wojtynek
AKAshutosh Kumar
Ashutosh Kumar
HBHarry Baird
Harry Baird
Katerina RadilovaKaterina Radilova
Katerina Radilova
KWKarsten Weis
Karsten Weis
The nuclear pore complex (NPC) forms a large channel that spans the double lipid bilayer of the nuclear envelope and is the central gateway for macromolecular transport between the nucleus and cytoplasm in eukaryotes. NPC biogenesis requires the coordinated assembly of over 500 proteins culminating in the fusion of the inner and outer nuclear membranes. The molecular mechanism of this membrane fusion step that occurs in all eukaryotes is unknown. Here, we elucidate the mechanism by which two paralogous transmembrane proteins, Brl1 and Brr6, mediate membrane fusion in S. cerevisiae. Both proteins form multimeric, ring-shaped complexes with membrane remodeling activity. Brl1 is enriched at NPC assembly sites via a nuclear export sequence and then interacts with Brr6 across the nuclear envelope lumen through conserved hydrophobic loops. Disrupting this interaction blocks fusion and halts NPC assembly. Molecular dynamics simulations suggest that the Brl1-Brr6 complex drives membrane fusion by forming a channel across bilayers that enables lipid exchange. Phylogenetic analyses reveal that Brl1/Brr6 homologues are broadly distributed across eukaryotes, and functional experiments in human cells and D. melanogaster establish CLCC1 as an NPC fusogen in metazoans. Together, our results uncover a novel, conserved mechanism for membrane fusion in eukaryotes.

11 November 2024 in ChemMedChem
Verified
Journal Article
Open access
MKMichal Kráľ
Michal Kráľ
TKTomáš Kotačka
Tomáš Kotačka
Robert ReibergerRobert Reiberger
Robert Reiberger
GPGabriela Panýrková
Gabriela Panýrková
Katerina RadilovaKaterina Radilova
Katerina Radilova
AMAleš Machara
Aleš Machara
The influenza RNA‐dependent RNA polymerase harbours an endonuclease subunit characterized by a catalytic site housing two divalent metal ions. By effectively chelating both Mg2+ and Mn2+ ions, a small‐molecule inhibitor with a metal‐binding pharmacophore can halt endonuclease activity. Herein, two 3’‐dehydroxypurpurogallin‐4‐carboxamide series, namely twelve C‐4’ unsubstituted and twelve C‐4’ phenyl substituted congeners were designed and prepared to be tested as inhibitors of the metal‐dependent viral enzyme. These inhibitors were accessed through the chemoenzymatic reaction of gallic acid with either pyrocatechol or phenylpyrocatechol moderated by laccase, followed by amidation. Experimental IC50 values were determined using AlphaScreen technology, with the most potent inhibitors exhibiting IC50 values around 0.35 μM. Using X‐ray crystallography, we analyzed structure of the endonuclease in complex with one potent 3’‐dehydroxypurpurogallin‐carboxamide at 2.0 Å resolution, revealing the coordination of the compound's triad of oxygen atoms with the two metal ions in the influenza A endonuclease active site.